Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience (Q45150263)

10 December 2017

Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience (English)

1 reference

10 December 2017

1 reference

2

1 reference

10 December 2017

Artz AS

1

1 reference

10 December 2017

Zimmerman T

3

1 reference

10 December 2017

Gajewski TF

4

1 reference

10 December 2017

Rini BI

5

1 reference

10 December 2017

Hu HS

6

1 reference

10 December 2017

Stadler WM

7

1 reference

10 December 2017

Vogelzang NJ

8

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Bone Marrow Transplantation

10 December 2017

1 reference

10 December 2017

35

1 reference

10 December 2017

253-260

1 reference

10 December 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704760

10 December 2017

0 references

cites work

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

In situ demonstration of renal-cell-carcinoma-specific T-cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Prognostic factors and value of adjunctive nephrectomy in patients with stage IV renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Advances in allogeneic stem cell transplantation: directing graft-versus-leukemia at solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

7 January 2021

Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

7 January 2021

Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

7 January 2021

Prognostic factors for the survival of patients with papillary renal cell carcinoma: meaning of histological typing and multifocality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

7 January 2021

Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

7 January 2021

Sensitivity of renal cell cancer to nonmyeloablative allogeneic hematopoietic cell transplantations: unusual or unusually important?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704760

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704760

1 reference

Dimensions Publication ID

10 December 2017

1014418737

0 references

Fatcat ID

release_runrdrwavne77gdqcxzsxhlixa

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/runrdrwavne77gdqcxzsxhlixa

24 November 2022

mapped directly with Wikidata item

1 reference